Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134: S136-S139
DOI: 10.1055/s-0029-1222590
DOI: 10.1055/s-0029-1222590
Kurzübersicht | Review article
Pharmakotherapie, Schlafmedizin© Georg Thieme Verlag KG Stuttgart · New York
Optimierung der Galenik von Analgetika zur Behandlung chronischer Schmerzzustände
Mögliche Auswirkungen auf SchlafstörungenOptimizing the galenical formulation of analgetics for the treatment of chronic pain conditionsPossible effects on sleep disordersFurther Information
Publication History
eingereicht: 11.11.2008
akzeptiert: 24.04.2009
Publication Date:
24 June 2009 (online)

Schlüsselwörter
Schmerzpflaster - End-of-dose-Versagen - Retardpräparat - Dose-Dumping
Keywords
transdermal patches - end-of-dose-failure - extended-release products - dose dumping
Literatur
- 1
Ackerman S J, Mordin M, Reblando J. et al .
Patient-reported utilization
patterns of fentanyl transdermal system and oxycodone hydrochloride
controlled-release among patients with chronic nonmalignant pain.
J Manag Care Pharm.
2003;
9
223-231
MissingFormLabel
- 2
Drover D R, Angst M S, Valle M. et al .
Input characteristics and bioavailability after
administration of immediate and a new extended-release formulation
of hydromorphone in healthy volunteers.
Anesthesiology.
2002;
97
827-836
MissingFormLabel
- 3
Gallagher R M, Welz-Bosna M, Gammaitoni A.
Assessment of dosing frequency of sustained-release
opioid preparations in patients with chronic nonmalignant pain.
Pain Med.
2007;
8
71-74
MissingFormLabel
- 4
Grond S, Radbruch L, Lehmann K A.
Clinical pharmacokinetics of transdermal opioids: focus on transdermal
fentanyl.
Clin Pharmacokinet.
2000;
38
59-89
MissingFormLabel
- 5
Miaskowski C.
Pharmacologic management of sleep disturbances in noncancer-related
pain.
Pain Management Nursing.
2008;
MissingFormLabel
- 6
Palangio M, Northfelt D W, Portenoy R K. et al .
Dose conversion
and titration with a novel, once-daily, OROS® osmotic technology,
extended-release hydromorphone formulation in the treatment of chronic
malignant or nonmalignant pain.
J Pain Symptom Manage.
2002;
23
355-368
MissingFormLabel
- 7
Radbruch L, Sabatowski R, Petzke F. et al .
Transdermal fentanyl for the management
of cancer pain: a survey of 1005 patients.
Palliat Med.
2001;
15
309-321
MissingFormLabel
- 8
Sathyan G, Guo C, Sivakumar K. et al .
Evaluation of the bioequivalence of two
transdermal fentanyl systems following single and repeat applications.
Current Medical Research and Opinion.
2005;
21
1961-1968
MissingFormLabel
- 9
Turk D C, Dworkin R H, Revicki D. et al .
Identifying important outcome domains for
chronic pain clinical trials: An IMMPACT survey of people with pain.
Pain.
2008;
137
276-285
MissingFormLabel
- 10
Visionenfür eine optimierte Opioidtherapie – 12. SocraTec Expertengespräch.
Deutsche Apotheker
Zeitung (DAZ).
2007;
147
49-50
MissingFormLabel
- 11 World Health Organisation .Cancer pain release appraising the Who Analgesic Ladder on its
20th anniversary. Geneve; WHO 2006
MissingFormLabel
- 12
Wonnemann M, Schug B, Schmücker K. et al .
Significant food interactions observed
with a nifedipine modified-release formulation marketed in the European
Union.
Intern J Clin Pharmacol Therapeut.
2006;
44
38-48
MissingFormLabel
- 13
Wonnemann M, Schug B, Anschütz M. et al .
Comparison of two marketed nifedipine modified-release
formulation: An exploratory clinical food interaction study.
Clin
Therapeutics.
2008;
30
1-11
MissingFormLabel
Prof. Dr. Henning Blume
SocraTec Research & Development
GmbH
Im Setzling 35
61440 Oberursel
Phone: 06171/58571-20
Fax: 06171/5857-25
Email: henning.blume@socratec-pharma.de